Topic: CRISPR

Support genome-engineering experiments using CRISPR-based methods, including prime editing and transcriptional activation or inhibition. Laboratory work includes cloning, viral transduction, cell culture and molecular analysis, with applications to stem-cell-derived brain-cell models and chromatin profiling. The advertised appointment is full-time for twelve months. Apply through the university’s Varbi recruitment system by 20 October 2026.

Two-year funded postdoctoral appointment in the Molecular Neuroscience laboratory, available from January 2027. Investigate membrane-protein assembly through CRISPR screens and mechanistic molecular, cellular, biochemical and structural experiments. The role includes independent research, protocol development, publication and team training. Apply with a CV, one-page motivation letter, one-page project proposal and two references through the contact specified in the advert. The employer states that applications containing AI-generated text will not be considered.

UC Berkeley Molecular & Cell Biology seminar (Divisions of Biochemistry, Biophysics & Structural Biology; Cell Biology, Development & Physiology; and Genetics, Genomics, Evolution & Development) by Luke Gilbert of UCSF on repurposing CRISPR systems to activate and silence genes.

H. Robert Horvitz's laboratory at MIT is recruiting a research technician to investigate molecular mechanisms of cell-fate determination and programmed cell death in Caenorhabditis elegans. The work includes genetic screens, CRISPR and transgenesis, molecular cloning, fluorescence microscopy, data analysis, animal husbandry, and general laboratory support in a highly integrative research environment.

Jennifer Doudna discusses how CRISPR changed gene editing and what might come next. The conversation examines emerging applications, technical limitations and the ethical choices involved in altering genetic material, including how scientific progress can be paired with responsible use.

The field of human biology faces three major technological challenges. Firstly, the causation problem is difficult to address in humans compared to model animals. Secondly, the complexity problem arises due to the lack of a comprehensive cell atlas for the human body, despite its cellular composition. Lastly, the heterogeneity problem arises from significant variations in both genetic and environmental factors among individuals. To tackle these challenges, we have developed innovative approaches. These include 1) mammalian next-generation genetics, such as Triple CRISPR for knockout (KO) mic

Glioblastoma cells trigger pharmacoresistant seizures that may promote tumor growth and diminish the quality of remaining life. To define the relationship between growth of glial tumors and their neuronal microenvironment, and to identify genomic biomarkers and mechanisms that may point to better prognosis and treatment of drug resistant epilepsy in brain cancer, we are analyzing a new generation of genetically defined CRISPR/in utero electroporation inborn glioblastoma (GBM) tumor models engineered in mice. The molecular pathophysiology of glioblastoma cells and surrounding neurons and untra

Human genes associated with brain-related diseases are being discovered at an accelerating pace. A major challenge is an identification of the mechanisms through which these genes act, and of potential therapeutic strategies. To elucidate such mechanisms in human cells, we established a CRISPR-based platform for genetic screening in human iPSC-derived neurons, astrocytes and microglia. Our approach relies on CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), in which a catalytically dead version of the bacterial Cas9 protein recruits transcriptional repressors or activators, respec